• KP Tissue lowered its 2026 capital spending outlook to CAD 80 million-CAD 100 million, including U.S. TAD expansion pre-engineering and strategic projects.
• Third-quarter capital spending totaled CAD 22.1 million, compared with CAD 15.5 million in the second quarter.
• The 2027 capital spending outlook is CAD 60 million-CAD 80 million, excluding strategic projects.
• NBSK pulp prices are expected to remain relatively stable through fourth-quarter 2026, with upward pressure in 2027.
• BEK pulp prices are forecast to remain stable in fourth-quarter 2026 and throughout 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KP Tissue Inc. published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.